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Abstract
Background: The purpose of this study is to investigate whether changes in brain microstructure, detected by
magnetization transfer imaging, are associated with cognition in older subjects at increased risk for vascular disease.
Methods: One hundred ninety three nondemented subjects (105 men, mean age 77 ± 3 years) from the Prospective
Study of Pravastatin in the Elderly at Risk were included. To assess cross-sectional associations between magnetization
transfer ratio (MTR) peak height and cognitive test scores, general linear model multivariate analysis was performed.
Models were adjusted for age, sex, education level, vascular risk factors, individual white matter lesion volume, and
brain atrophy. A repeated measures general linear model was used to investigate whether MTR peak height relates to
cognitive test performance at baseline and 3.3-year follow-up.
Results: Cross-sectionally, MTR peak height was associated with performance on the STROOP test (unstandardized
β = −0.27, p = 0.045), delayed Picture Word Learning (PWL) test (β = 0.48, p = 0.007), and the Letter Digit Coding
test (β = 1.1, p = 0.006). Repeated measures general linear model analysis showed that individuals with low MTR
peak height at baseline performed worse on the STROOP test compared to subjects with intermediate MTR peak
height (mean time to complete the test at baseline and follow-up, lower versus middle tertile of MTR peak height: 61.6
versus 52.7 s, p = 0.019) or compared to subjects with high MTR peak height (p = 0.046). Similarly, low MTR peak height
was associated with worse performance on the immediate (lower versus middle tertile, p = 0.023; lower versus higher
tertile, p = 0.032) and delayed PWL test (lower versus middle, p = 0.004; lower versus higher, p = 0.012) at baseline and
follow-up testing.
Conclusions: MTR peak height is associated with cognitive function in older subjects at increased risk for vascular
disease.
Background
Age-related cognitive decline is of increasing concern
among the elderly, still, the underlying mechanisms are
incompletely understood [1]. Magnetic resonance imaging
(MRI) enables in vivo characterization of visible cerebral
changes occurring with both advancing age and cognitive
decline, such as brain atrophy, the presence of small vessel
disease, and basal ganglia iron depositions [2–4].
In addition to these overt MRI visible abnormalities,
‘hidden’ changes in brain tissue integrity can be assessed
by magnetization transfer imaging [5]. It has been shown
that lower magnetization transfer ratio (MTR) relates to
decreasing myelin content and axonal count in both grey
and white matter [6, 7]. There is a significant MTR de-
crease with advancing age [8, 9]. Currently, MTR metrics
have been used extensively to evaluate brain microstruc-
ture in different neurodegenerative diseases [10–17].
Recently it has been shown that low MTR values correl-
ate cross-sectionally with cognitive impairment in nonde-
mented older subjects [18, 19]. However, no longitudinal
studies have been performed investigating the association
between MTR and cognitive changes over time.
Therefore at present it is unclear whether MTR has a
role in predicting cognitive decline. Nevertheless, it has
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been put forward that MTR may be a useful outcome
marker that is required to monitor disease progression
and assess clinical intervention studies in demented and
nondemented older subjects [18].
The purpose of this study is to investigate whether base-
line MTR, a marker of brain microstructure, relates to
cognition at baseline and 3.3-year follow-up in an older
population at increased risk for vascular disease.
Methods
The Prospective Study of Pravastatin in the Elderly at Risk
(PROSPER study) has ethics review board approval of all
locations. The individual ethics committees are listed in
an additional file 1. Written informed consent was ob-
tained from all participants. In addition, our local institu-
tional ethics review board (the Medical Ethics Committee
of the Leiden University Medical Center) approved the
research protocol for the prospective MRI study and sub-
sequent retrospective analyses. Participants of the current
MRI study also agreed with retrospective analysis of their
MRI data for research purposes.
Study subjects
Subjects were included from the PROSPER Study which
has been described in more detail elsewhere [20]. In
short, subjects were enrolled based on the following
inclusion criteria: (1) age 70–82 years, (2) total choles-
terol 4.0 – 9.0 mmol/L, (3) transient ischemic accident,
stroke, myocardial infarction, arterial surgery or ampu-
tation due to vascular disease >6 months prior to study
entry, (4) ≥1 risk factors for vascular disease: hypertension
or currently receiving drug treatment, current smoker,
fastening blood glucose > 7 mmol/L or known diabetes
mellitus. Subjects with poor cognitive function at baseline
(Mini Mental State Examination (MMSE) < 24) were ex-
cluded. More detailed exclusion criteria have been de-
scribed elsewhere [20].
Inclusion of participants for the nested MRI substudy
has been described elsewhere [21]. Participants were in-
cluded from the Dutch sample of the PROSPER Study.
The Medical Ethics Committee of the Leiden University
Medical Center approved the study. A total number of
554 study participants had a baseline MRI scan and cogni-
tive testing at both baseline and 3.3 year (range 2.9 to
3.8 year) follow-up. Magnetization transfer imaging was
introduced to the scan protocol halfway during subject
inclusion and performed in the last 193 consecutive sub-
jects at baseline. In this retained sample, data on cognitive
testing at baseline and 3.3 year follow-up were available in
all individuals. There was no missing data nor outliers.
Measures of cognitive function
Cognitive function was assessed at baseline and subse-
quently at follow-up. MMSE is widely used to screen for
cognitive dysfunction [22]. As MMSE scores were used as
exclusion criteria, they are not reported in association
with MRI markers. We used the abbreviated Stroop Color
Word Test to assess executive functioning and attention,
and measured the time to complete the color interference.
All study participants were screened for color blindness.
Memory function was evaluated with the Picture Word
Learning Test (PWLT), which consists of 12 pictures
which subjects should recall in any order. Accordingly, we
used the average number of items reported correctly in 3
conditions requiring immediate recall (immediate PWLT)
and the sum of the number of items correctly recalled in
the delayed condition (delayed PWLT). With the Letter
Digit Coding Test (LDCT), which evaluates speed of pro-
cessing of general information and tests visual scanning,
visual memory, perception, visuoconstruction and motor
functions, we assessed the number of correct digits. De-
scriptions of the cognitive tests and the procedures have
been reported previously [23]. High test/re-test correla-
tions for the STROOP and LDCT and acceptable test/re-
test correlations for the immediate and delayed PWLT
have been reported [23]. A small but clinically relevant
improvement in cognitive test performance has been
observed after testing twice with two weeks in between.
By using parallel versions for the PWLT and the LDCT
and redundant for the Stroop test, the possibility that
study participants had remembered specific material
from a test version can be ruled out. It has been suggested
that practice effects should be taken into account when
following the course of cognitive functions in individuals
over time [23].
Depressive symptoms were measured at baseline with
the 15-item Geriatric Depression Scale (GDS-15) [24]. We
defined depression as a score of 4 points or more, and no
depression as a score of 3 points or less on the GDS-15.
MRI scanning
Imaging was performed on a Philips Gyroscan Intera ACS-
NT 1.5T MR scanner (Philips Medical Systems, Best, The
Netherlands). Axial proton-density (repetition time [TR]/
echo time [TE] 2500/30 msec), T2-weighted (TR/TE 2500/
120 msec), and fluid-attenuated inversion recovery (FLAIR;
TR/inversion time/TE 8000 msec/2000 msec/120 msec) im-
ages were acquired with the following parameters: field of
view (FOV) 220 mm, matrix 256 × 256, and 22 6-mm slices
with 0.6-mm slice gap. Magnetization transfer (three-di-
mensional gradient-echo pulse sequence, slice thick-
ness = 5 mm; 28 slices, no gap; TR/TE = 106/6; FA = 120;
FOV = 220 mm; matrix = 56 × 256; 1100 Hz below water
frequency saturation pulse) images were obtained in all
subjects. Raw magnetization transfer scans were split into
the M0-sequence, which was acquired without the satur-
ation pulse and the M1-sequence, which was acquired
after application of a saturation pulse.
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Intracranial volume, brain tissue volume, and total
white matter hyperintensity volume were automatically
quantified on T2-weighted and FLAIR images using
Software for Neuro-Image Processing in Experimental
Research [25]. We defined brain atrophy (%) as follows:
[(intracranial volume – brain tissue volume)/intracra-
nial volume] × 100 % [26].
T1-weighted images were skull-stripped using brain
extraction tool [27] and subsequently segmented using
FMRIB’s automated segmentation tool [28] and FMRIB’s
integrated registration and segmentation tool [29], result-
ing in individual brain masks. The T1 weighted images
were subsequently registered to the non-saturated M0
image using FMRIB’s registration tool, and the transform-
ation matrix of this registration was saved.
In magnetization transfer imaging, MTR is the most
commonly used measure, reflecting the efficiency of
magnetization exchange between protons in tissue com-
pared with surrounding water [30]. Individual MTR maps
were calculated voxel by voxel following the equation
MTR = (M0-M1)/M0. Low MTR is usually considered
indicative of damage to myelin and other cellular struc-
tures. We evaluated both gray and white matter together,
yielding a measure of overall brain damage. The frequency
distribution of all MTR values was displayed as histo-
grams. A bin size of 0.01 and 100 bins was used. To
reduce partial-volume effects, a threshold of 0.20 was used
to remove any remaining voxels that might still be con-
taminated with cerebrospinal fluid. The peak height of the
histogram indicates the number of voxels that show the
most common MTR value per region of interest [15]. Re-
gion of interest was defined as total brain parenchyma
(gray and white matter) in our study. In healthy individ-
uals, the histogram is characterized by a single sharp peak,
indicating that normal brains are relatively homogeneous
in terms of MT imaging characteristics. Decreased MTR
peak height may be indicative of brain tissue decline [15].
It has been shown previously that MTR histogram peak
height is a sensitive marker of changes in brain tissue
integrity [31–34]. The peak height of the MTR histogram
was divided by the number of voxels of brain tissue to
normalize for brain size [15]. MT-MRI measures did not
exceed - 3 or + 3 standard deviations.
Statistical analysis
Data are presented as mean with standard deviation, un-
less stated otherwise. MMSE scores at baseline and
follow-up were compared using paired-samples T test. To
assess cross-sectional associations between tertiles of
MTR peak height and cognitive test scores, general linear
model multivariate analysis was performed with two-step
modeling. The first model included age and education as
covariates and sex as fixed factor. Estimated regression co-
efficients are reported for this model. Next, we used a
model that adjusted for age, sex, education, systolic and
diastolic blood pressure, body mass index, smoking, his-
tory of vascular disease, individual total white matter le-
sion load, and brain atrophy. Tertiles of MTR were
obtained by a tertiary split of the numerical MTR variable,
thereby dividing the data into three categories of equal
number. Scores were determined at the 33rd and 66th
percentiles.
A repeated measures general linear model was used to
investigate whether tertiles of MTR peak height at base-
line relate to cognitive test performance at baseline and
3.3-year follow-up. We defined baseline and follow-up
cognitive test performance as within-subjects variables
and tertile of baseline MTR peak height as between-
subjects factors. Post hoc testing was performed with
Bonferroni correction. For statistical analyses, Statistical
Package for the Social Sciences (SPSS) software for win-
dows (version 20.0) was used. P values less than 0.05
were considered statistically significant.
Results
The current study cohort consisted of 193 subjects. There
were 105 men and 88 women with a mean ± standard de-
viation age of 77.6 ± 3.2 years. Subject characteristics are
shown in Table 1. MMSE scores at baseline and follow-up
were 28.1 ± 1.5 and 28.4 ± 2.1, respectively, p = 0.025. Eight
individuals declined into possible dementia according to
MMSE scores at follow-up (e.g. MMSE score < 24). Me-
dian GDS-15 score at baseline was 1 (interquartile range
0–2). Six individuals (3 %) had a GDS-15 score ≥ 4 points.
Cross-sectional associations between MTR peak height
and cognitive function are shown in Table 2. Results
from general linear model multivariate analysis showed
a negative association between MTR peak height and
test results on the STROOP test (unstandardized β = −3.9,
p = 0.002). In this model, estimated regression coefficients
are β = 1.3 (p < 0.001) for age and β = −1.6 (p < 0.001) for
education. In the fully adjusted model, association be-
tween MTR peak height and STROOP test remained
significant (β = −0.27, p = 0.045). There was a positive
association between MTR peak height and test results on
the immediate PWL test (β = 0.33, p = 0.004) after adjust-
ing for age, sex, and education. In this model, estimated
regression coefficients are β = −0.11 (p < 0.001) for age
and β = 0.11 for education (p = 0.001). In the fully ad-
justed model, association between MTR peak height
and immediate PWL test attenuated (β = 0.24, p = 0.058).
There was a positive association between MTR peak
height and test results on the delayed PWL test (β =
0.59, p < 0.001) after adjusting for age, sex, and educa-
tion. In this model, estimated regression coefficients
are β = −0.14 (p = 0.001) for age and β = 0.10 for educa-
tion (p = 0.027). In the fully adjusted model, association
between MTR peak height and delayed PWL test
Sala et al. BMC Neurology  (2015) 15:133 Page 3 of 7
remained significant (β = 0.48, p = 0.007). There was a
positive association between MTR peak height and test re-
sults on the LDC test (β = 1.6, p < 0.001) after adjusting
for age, sex, and education. In this model, estimated re-
gression coefficients are β = −0.36 (p < 0.001) for age and
β = 0.85 for education (p < 0.001). In the fully adjusted
model, association between MTR peak height and the
LDC test remained significant (β = 1.1, p = 0.006).
Difference in cognitive test performance at 3.3-year
follow-up versus baseline across tertiles of MTR peak
height is shown in Fig. 1. General linear model repeated
measures analysis showed that individuals with low
MTR peak height at baseline required more time to
complete the STROOP test compared to subjects with
intermediate MTR peak height (mean time to complete
the test at baseline and follow-up, lower versus middle
tertile of MTR peak height: 61.6 versus 52.7 s, p = 0.019)
and compared to subjects with high MTR peak height
(lower versus higher tertile, 61.6 versus 53.7 s, p = 0.046).
For individuals with low MTR peak height, average num-
ber of items reported correctly on the immediate PWLT
was lower compared to individuals with intermediate
MTR peak height (average number of items reported
correctly at baseline and follow-up, lower versus middle
tertile, 9.5 versus 10.4 items, p = 0.023) and compared
to individuals with high MTR peak height (lower versus
higher tertile, 9.5 versus 10.3 items, p = 0.032). Simi-
larly, for individuals with low MTR peak height, average
number of items reported correctly on the delayed
PWLT was lower compared to individuals with inter-
mediate MTR peak height (lower versus middle tertile,
10.1 versus 11.5 items, p = 0.004) and high MTR peak
height (lower versus higher tertile, 10.1 versus 11.3
items, p = 0.012).
The average number of correct digits reported at base-
line and follow-up on the LDCT was not different across
tertiles of MTR peak height.
In none of the cognitive domains a difference in test
performance at baseline and follow-up was found between
subjects with intermediate and high MTR peak height.
Table 1 Baseline characteristics
Continuous variables Values
Subjects, n 193
Age in years 77.6 (3.2)
Education, age at leaving school 15.2 (2.8)
Body mass index in kg/m2 26.8 (3.5)
Systolic blood pressure, mm Hg 158.4 (22.3)
Diastolic blood pressure, mm Hg 83.6 (10.0)
Fasting glucose, mmol/L 5.9 (1.7)
Total cholesterol, mmol/L 5.0 (1.1)
High density lipoprotein cholesterol, mmol/L 1.3 (0.4)
Triglycerides, mmol/L 1.4 (0.7)
Baseline mini mental state examination score, points 28.4 (2.1)
Baseline stroop test score, seconds 56.6 (23.4)
Immediate picture-word learning test score, words 10.1 (2.1)
Delayed picture-word learning test, words 10.9 (3.0)
Letter-digit coding test score, digits/min 26.0 (7.0)
MRI features
Grey matter in mL 465.6 (59.1)
White matter in mL 609.3 (70.2)
Brain atrophy, percentage 26.1 (3.2)
White matter hyperintensity volume in mL 5.1 (9.5)
Categorical variables
Male, n (%) 105 (54)
Current smoking, n (%) 28 (15)
History of diabetes mellitus, n (%) 41 (21)
History of transient ischemic attack or stroke, n (%) 29 (18)
Ischemic cortical infarction, n (%) 7 (4)
Lacunar infarction, n (%) 9 (5)
History of myocardial infarction, n (%) 28 (15)
Use of anticholinergics, n (%) 10 (5)
Use of antiepileptics, n (%) 0 (0)
Use of antipsychotics, n (%) 0 (0)
Use of benzodiazepines, n (%) 10 (5)
Values are means (standard deviation) unless stated otherwise
Table 2 Cross-sectional association between magnetization transfer ratio peak height and cognition
Tertile of MTR peak height
Lower Middle Upper β P-value
STROOP 63.6 (29.3 – 189.3) 55.4 (29.4 – 105.3) 49.9 (30.0 – 98.3) −0.27 0.045
PWLT immediate 9.7 (3.0 – 15.0) 9.8 (4.0 – 15.0) 10.9 (6.0 – 13.3) 0.24 0.058
PWLT delayed 10.1 (3.0 – 15.0) 10.8 (1.0 – 15.0) 12.1 (7.0 – 15.0) 0.48 0.007
LDCT 23.8 (9.0 – 40.0) 25.5 (11.0 – 36.0) 28.7 (14.0 – 43.0) 1.1 0.006
Absolute values for cognitive function tests per tertile of MTR peak height are shown (mean [minimum - maximum]). P-values and unstandardized β are shown
for general linear model multivariate analysis, adjusting for age, sex, education, systolic and diastolic blood pressure, body mass index, smoking, history of
vascular disease, individual total white matter lesion load, and brain atrophy
Stroop Stroop test, time in seconds to complete test, PWLT Picture Word Learning Test, number of items correctly recalled in immediate or delayed condition.
LDCT Letter Digit Coding Test, number of correct digits
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Discussion
The main finding of our study is that MTR peak height
relates to cognitive test performance at baseline and
3.3-year follow-up in an older population at risk for
vascular disease. MT-MRI nowadays has become in-
creasingly useful in detecting microstructural cerebral
changes that are correlated with cognitive decline in a
variety of neurodegenerative diseases [10–17]. However,
the cause and effect of the relation between diminished
cognition and MTR changes in the brain in cross-
sectional study designs remains unsolved. The present
study aims at investigating the association between MTR
and two longitudinal measures of cognition in neurologic-
ally asymptomatic older individuals at increased risk for
vascular disease.
Few studies investigated the association between MTR
and cognition in neurologically asymptomatic people. One
recent study of an older population showed that lower
MTR is related to memory impairment, executive dys-
function, and impaired motor skills [18].
In contrast, two other studies found no relation between
brain MTR and cognition in healthy subjects [9, 35]. Our
data unequivocally show that MTR peak height is cross-
sectionally associated with cognition, as assessed by the
STROOP test, the delayed Picture Word Learning test,
and the Letter Digit Coding test. Although we included
neurologically asymptomatic subjects in the present study,
subjects were included from the PROSPER Study, which
implies that all subjects had an increased vascular risk
profile. It is well known that an increased vascular risk
profile is the most important factor in developing cere-
bral damage related to small vessel disease, white mater
lesions, and atrophy [36]. Both white mater lesions and
atrophy directly affect MTR peak height [9]. It should
Fig. 1 Difference in Cognition at 3.3-year Follow-Up versus Baseline across Tertiles of MTR peak height. a, STROOP test, difference in time (seconds) to
complete test; (b and c): immediate and delayed Picture Word Learning Test (PWLT), difference in the average number of items reported correctly in 3
conditions requiring immediate recall (immediate PWLT) and the sum of the number of items correctly recalled in the delayed condition (delayed
PWLT); (d): Letter Digit Coding test (LDCT), difference in the number of correct digits. Bar graphs represent means ± standard error of the mean.
P-values are from repeated measures general linear model with post hoc Bonferroni test, which was used to investigate whether tertiles of MTR peak
height at baseline relate to cognitive test performance at baseline and 3.3-year follow-up. * P < 0.05 and ** p < 0.01
Sala et al. BMC Neurology  (2015) 15:133 Page 5 of 7
be realized that extensive vascular damage such as large
confluating white matter lesions, cortical ischemic or
haemorrhagic infarcts strongly affect the relationships
described in the present study. To reduce the con-
founding effects of both vascular risk factors and the
presence of manifest vascular brain damage, analyses
were corrected for both factors. Additionally, to reduce
potential partial volume effects in calculating MTR
values brain parenchyma was eroded by one MTR voxel
in all three dimensions.
In addition to the associations found cross-sectionally,
our data show that individuals with low MTR peak height
at baseline performed worse on the STROOP test and the
immediate and delayed PWLT compared to individuals
with intermediate or high MTR peak height at baseline
and follow-up testing. It might be the case that subjects
with low MTR peak height at baseline develop a faster
cognitive decline than subjects with intermediate or high
MTR peak height. On the other hand, our data do not
show that cognitive test performance is different in in-
dividuals with high MTR peak height compared to indi-
viduals with intermediate MTR peak height. Our data
indicate a J-shape relation between MTR peak height
and cognition with low MTR peak height reflecting
greatest change in cognition. It can be speculated that
in subjects with low MTR peak height, MTR reflects
irreversible microstructural damage that is not present
in the other tertiles.
MTR imaging has been used to probe the integrity of
macromolecular proteins and phospholipids in the
brain. Post mortem imaging and histopathology studies
of multiple sclerosis have shown that in white matter
lower MTR is associated with axonal loss and myelin
compromise [37, 38]. In gray matter, reduction in den-
dritic density and neuronal size or number and damage
to cell membranes may collectively or independently
lead to decreased MTR [39]. We used whole brain
MTR analyses, yielding a measure of overall brain tissue
integrity. It should be noted that the lack of anatomical
specificity limits the interpretation of the source of
differences in MTR. Still, our results indicate that MTR
as a marker of macromolecular degeneration relates to
cognition.
The following study limitations should be considered.
First, subject inclusion for this study was restricted to sub-
jects enrolled in the PROSPER Study. Therefore, our study
cohort consists of older subjects with or at increased risk
for vascular disease which may limit extrapolation to the
general population. However, with population aging, and
given the high prevalence of vascular risk factors in the
elderly, our study cohort in fact represents a substantial
part of the aging population.
Second, having only two longitudinal measurements has
limited our study to estimate linear change in cognition
only [40] whereas more than three measurement occasions
would have enabled investigation of nonlinear change.
Third, it has been proposed that accumulation of sub-
cortical iron is a risk factor for neuronal and cognitive
decline in normal aging [41]. In addition, brain iron may
affect automated brain segmentation procedures and
MTR measures [42, 43]. Therefore, in general, differential
iron distribution in the brain may constitute bias that
should be considered in computational anatomy studies of
ageing and neurodegeneration.
Finally, longitudinal stability of MTR measures in our
study is unknown which is a study limitation.
Conclusions
MTR peak height relates to cognitive test performance
at baseline and 3.3-year follow-up in an older popula-
tion at risk for vascular disease. MTR histogram peak
height may be a potentially useful marker of cognition
in future clinical intervention studies.
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